阿法替尼
医学
脑转移
肺癌
肿瘤科
转移
肺
内科学
癌症
表皮生长因子受体
埃罗替尼
作者
Limei Sun,Bing Li,Bin Wang,Jinduo Li,Jing Li
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2021-07-12
卷期号:33 (1): 112-118
标识
DOI:10.1097/cad.0000000000001138
摘要
Brain metastasis is one of the common distant metastases of lung cancer. The prognosis of patients with brain metastasis is worse and the survival time is shorter. In this report, we described a rare mutation of EGFR G2607A (rs1050171) in two patients over 50 years of age with brain metastasis of lung cancer. These two patients were both treated with afatinib, followed up for 13 months and 45 months respectively. Both patients showed that the tumor subsided, the curative effect was identified as partial response (PR), no recurrence and progress occurred and still being under follow-up. Our study provides a support that afatinib may be a reasonable therapeutic option for patients with brain metastasis of lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI